BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/21/2022 2:30:44 AM | Browse: 24 | Download: 65
Publication Name World Journal of Cardiology
Manuscript ID 74514
Country/Territory India
2021-12-26 21:18
Peer-Review Started
2021-12-26 21:20
To Make the First Decision
Return for Revision
2022-03-16 01:59
2022-03-17 23:22
Second Decision
2022-05-20 03:08
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-05-23 00:47
Articles in Press
2022-05-23 00:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
2022-05-31 11:28
Typeset the Manuscript
2022-06-08 10:38
Publish the Manuscript Online
2022-06-21 01:59
ISSN 1949-8462 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology and Metabolism
Manuscript Type Opinion Review
Article Title Metabolic and cardiovascular benefits with SGLT-2 inhibitors and GLP-1 receptor agonists combination therapy in type 2 diabetes
Manuscript Source Invited Manuscript
All Author List Awadhesh Kumar Singh and Ritu Singh
Funding Agency and Grant Number
Corresponding Author Awadhesh Kumar Singh, MBBS, MD, PhD, Consultant Physician-Scientist, Intermediate Editor, Senior Postdoctoral Fellow, Senior Researcher, Department of Diabetes and Endocrinology, G.D Hospital and Diabetes Institute, No. 3 Canal Street, Kolkata 700013, India. draksingh_2001@yahoo.com
Key Words GLP-1 receptor agonists; SGLT-2 inhibitors; Combination therapy, Metabolic outcomes; Cardiovascular outcomes; Renal outcomes
Core Tip GLP-1 receptor agonists (GLP-1RA) plus SGLT-2 inhibitors (SGLT-2I) dual therapy causes a greater reduction in HbA1c, body weight, and systolic blood pressure (SBP), compared to either agent alone with similar adverse events. However, lowering of HbA1c, body weight, and SBP with combination therapy appeared to be less, nearly equal, and more than additive, respectively, compared to the sum of either agent alone. Our meta-analysis from 5 cardiovascular outcome trials suggests a similar reduction in major adverse cardiovascular events with dual therapy compared to GLP-1RA or SGLT-2I alone, but an additional benefit in heart failure hospitalization is likely. Future trials are needed to confirm these findings.
Publish Date 2022-06-21 01:59
Citation Singh AK, Singh R. Metabolic and cardiovascular benefits with SGLT-2 inhibitors and GLP-1 receptor agonists combination therapy in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342
URL https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm
DOI https://dx.doi.org/10.4330/wjc.v14.i6.329
Full Article (PDF) WJC-14-329.pdf
Full Article (Word) WJC-14-329.docx
Manuscript File 74514_Auto_Edited-HZ-FilipodiaCL-LS_WangTQ.docx
Answering Reviewers 74514-Answering reviewers.pdf
Audio Core Tip 74514-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 74514-Conflict-of-interest statement.pdf
Copyright License Agreement 74514-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 74514-Language certificate.pdf
Supplementary Material 74514-Supplementary material.pdf
Peer-review Report 74514-Peer-review(s).pdf
Scientific Editor Work List 74514-Scientific editor work list.pdf